50,000 Shares in Carlsmed, Inc. $CARL Bought by Ghisallo Capital Management LLC

Ghisallo Capital Management LLC purchased a new stake in Carlsmed, Inc. (NASDAQ:CARL) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 50,000 shares of the company’s stock, valued at approximately $670,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of CARL. Boston Partners bought a new position in shares of Carlsmed in the third quarter valued at $393,000. BNP Paribas Financial Markets acquired a new position in shares of Carlsmed during the third quarter valued at about $33,000. Russell Investments Group Ltd. bought a new stake in shares of Carlsmed during the third quarter worth about $2,128,000. Monashee Investment Management LLC acquired a new stake in shares of Carlsmed in the 3rd quarter worth about $536,000. Finally, Vanguard Group Inc. acquired a new stake in shares of Carlsmed in the 3rd quarter worth about $3,042,000.

Wall Street Analyst Weigh In

CARL has been the subject of a number of analyst reports. Wall Street Zen upgraded Carlsmed from a “sell” rating to a “hold” rating in a research note on Saturday, February 14th. BTIG Research reissued a “buy” rating and issued a $24.00 price objective on shares of Carlsmed in a research note on Monday, December 15th. The Goldman Sachs Group restated a “buy” rating and issued a $20.00 target price on shares of Carlsmed in a report on Friday, January 9th. Zacks Research cut Carlsmed from a “hold” rating to a “strong sell” rating in a research report on Wednesday, February 25th. Finally, Weiss Ratings reissued a “sell (e-)” rating on shares of Carlsmed in a research report on Monday, December 22nd. Three equities research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $21.33.

Carlsmed Stock Performance

Carlsmed stock opened at $11.40 on Friday. Carlsmed, Inc. has a fifty-two week low of $10.65 and a fifty-two week high of $17.19. The company has a current ratio of 8.87, a quick ratio of 8.74 and a debt-to-equity ratio of 0.16. The stock’s 50-day moving average price is $12.51. The stock has a market capitalization of $304.72 million and a PE ratio of -3.11.

Carlsmed (NASDAQ:CARL) last posted its quarterly earnings data on Wednesday, February 25th. The company reported ($0.32) EPS for the quarter, beating the consensus estimate of ($0.43) by $0.11. Carlsmed had a negative net margin of 58.67% and a negative return on equity of 72.60%. The firm had revenue of $15.16 million during the quarter, compared to analyst estimates of $15.20 million.

About Carlsmed

We are a commercial-stage medical technology company pioneering AI-enabled personalized spine surgery solutions with a mission to improve outcomes and decrease the cost of healthcare for spine surgery and beyond. We are focused on becoming the standard of care for spine fusion surgery. The aprevo Technology Platform consists of artificial intelligence (“AI”)-enabled software solutions, and interbody implants that we custom design for each patient’s unique pathology and vertebral bone topography, and single-use surgical instruments (the “aprevo Technology Platform”).